Ex-Biocon team, Symbio Generrics completes capital raise from Ascent Capital

The team is focused on building a high-potential generics API portfolio for the global markets and to this effect, will work towards getting US FDA and other SRA approvals for their recently acquired facilities.Commenting on the fund raise, Salim Shaikh, Executive Chairman Founder of Symbio Generrics, said , We are glad to be associated with Ascent Capital which has a reputation of partnering with entrepreneurs to build leading businesses in India.

Symbio Generrics India Private Limited (Symbio), a specialized Active Pharmaceutical Ingredients (API) & Intermediates manufacturing and marketing organization, announced today that it has completed an equity capital raise from Ascent Capital, a leading growth-capital focused private equity fund.

Symbio was founded by pharmaceutical professionals, Salim Shaikh and Abhijit Kale. They were soon joined by the third promoter, Akash Puranik; all of whom possess decades of experience in the global pharmaceutical industry. Symbio's journey from a sales and marketing organization to a full-fledged vertically integrated manufacturer of specialized APIs has been exemplary. Through a well-developed customer ecosystem, the highly experienced & skilled team at Symbio has established a global footprint for its APIs. Ascent Capital's sizeable investment in Symbio will further accelerate the company's expansion plans and sets the company enroute to emerge as a top-10 manufacturer of APIs in India.

The funds raised from Ascent will be utilized towards undertaking strategic acquisitions, establishing a best-in-class R&D facility and ramping up manufacturing capacity. The company's R&D Centre is housed in Bengaluru while the manufacturing plant is located at Dobbaspet, Bengaluru. The Company is in the process of acquiring another manufacturing facility in India. The team is focused on building a high-potential generics API portfolio for the global markets and to this effect, will work towards getting US FDA and other SRA approvals for their recently acquired facilities.

Commenting on the fund raise, Salim Shaikh, Executive Chairman & Founder of Symbio Generrics, said , ''We are glad to be associated with Ascent Capital which has a reputation of partnering with entrepreneurs to build leading businesses in India. The sizeable investment from Ascent Capital will add power to our next growth spurt and enable us to emerge as a top-10 API company in India. We are setting ourselves a medium-term goal of growing rapidly into a sizeable company by leveraging the strength of our team and expanding our horizons to actively serve the global API market.'' Akash Puranik, Promoter, MD& CEO of Symbio Generrics, says , ''The latest feather in our cap is the influx of resources from Ascent Capital. We have carved strategic alliances and relationships spanning over two decades with leading pharmaceutical entities in regulated and semi-regulated markets and are now keen to expand these synergies further in the global arena. With a well-developed infrastructure, both on the manufacturing and R&D front, we are keen to engage with potential partners for CDMO Business.'' Mr. Raja Kumar, Founder and MD of Ascent Capital, said, ''Ascent Capital has been known to support highly qualified professional teams in niche domains. Continuing with this tradition, we are delighted to partner with the first-generation technocrat founders at Symbio. Collectively, the team at Symbio is one of the best multi-disciplinary teams in the Indian pharma space and has shown an exemplary track record of building global relationships. We look forward to working collaboratively with the Company to ensure that we have another category leader from the Ascent stable, akin to BigBasket, Sequent, Skanray, to name a few.'' IC Universal Legal's Chennai team led by Senior Partner, Sameena Chatrapathy represented Symbio as the legal counsel for the fund raise from Ascent Capital as well as the follow-on acquisitions.

About Symbio Symbio Generrics India Private Limited (Symbio), founded in the year 2010 is a specialized Active Pharmaceutical Ingredients (API) & Intermediates manufacturing and marketing organization with headquarters in Bengaluru. The Company was founded by first generation entrepreneurs coming from a leading pharmaceutical organization, with a combined experience of over 40 years.

Symbio was focused on trading till recently, and now has 2 (two) manufacturing facilities located at Vizag and Bengaluru. The Company also has a state-of-the-art R&D centre at Jigani, Bengaluru. The Company currently employs over 100 people including 15 scientists to fuel the R&D pipeline and it is proposed to double the employee count by end of this fiscal.

About Ascent Capital Ascent Capital is a leading India-focused Independent Private Equity Fund Manager. The team at Ascent is one of the most experienced investment teams in India with 150+ years of collective experience in Indian PE and capital markets. Thus far, Ascent has helped more than 60 entrepreneurs build leading businesses across diverse sectors such as Technology, Healthcare, Financial Services, Consumer Brands, etc. It typically invests USD 10-30 MM in fast growing businesses, led by outstanding entrepreneurs, that have the potential to emerge as leaders in its segment thereby delivering exceptional exit outcomes. Ascent is backed by marquee investors, who include long term institutional investors like pension funds, foundations, endowments, fund of funds and large corporations - a vote of confidence in the team's ability to excel and deliver results.

Know more about Symbio Generrics: www.symbiogenerics.com Know more about Ascent Capital: https://ascentcapital.in/ Photo: https://mma.prnewswire.com/media/1954974/Akash_Puranik_Salim_Shaikh.jpg

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)